Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for aTyr Pharma, Inc. (ATYR : NSDQ)
 
 • Company Description   
aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States.

Number of Employees: 59

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.82 Daily Weekly Monthly
20 Day Moving Average: 5,164,718 shares
Shares Outstanding: 97.99 (millions)
Market Capitalization: $80.04 (millions)
Beta: 0.81
52 Week High: $7.29
52 Week Low: $0.68
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -22.93% -24.95%
12 Week -83.33% -84.02%
Year To Date -77.43% -80.28%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
10240 Sorrento Valley Road Suite 300
-
SAN DIEGO,CA 92121
USA
ph: 858-731-8389
fax: 858-731-8394
investorrelations@atyrpharma.com http://www.atyrpharma.com
 
 • General Corporate Information   
Officers
Sanjay S. Shukla - President; Chief Executive Officer and Director
Timothy P. Coughlin - Chairman of the Board
Jill M. Broadfoot - Chief Financial Officer
Eric Benevich - Director
John K. Clarke - Director

Peer Information
aTyr Pharma, Inc. (CORR.)
aTyr Pharma, Inc. (RSPI)
aTyr Pharma, Inc. (CGXP)
aTyr Pharma, Inc. (BGEN)
aTyr Pharma, Inc. (GTBP)
aTyr Pharma, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 002120202
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/12/26
Share - Related Items
Shares Outstanding: 97.99
Most Recent Split Date: 7.00 (0.07:1)
Beta: 0.81
Market Capitalization: $80.04 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.18 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.73 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 03/12/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.00
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -13.04%
vs. Previous Quarter: -18.18%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
09/30/25 - -100.36
06/30/25 - -93.69
03/31/25 - -87.09
ROA
09/30/25 - -74.70
06/30/25 - -68.83
03/31/25 - -64.77
Current Ratio
09/30/25 - 5.93
06/30/25 - 5.63
03/31/25 - 7.79
Quick Ratio
09/30/25 - 5.93
06/30/25 - 5.63
03/31/25 - 7.79
Operating Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Net Margin
09/30/25 - -
06/30/25 - -
03/31/25 - -
Pre-Tax Margin
09/30/25 - -39,540.53
06/30/25 - -
03/31/25 - -
Book Value
09/30/25 - 0.82
06/30/25 - 0.84
03/31/25 - 0.84
Inventory Turnover
09/30/25 - -
06/30/25 - -
03/31/25 - -
Debt-to-Equity
09/30/25 - 0.00
06/30/25 - 0.01
03/31/25 - 0.01
Debt-to-Capital
09/30/25 - 0.49
06/30/25 - 0.80
03/31/25 - 0.99
 

Powered by Zacks Investment Research ©